Business Context and Reporting Period
This Form 8-K is filed by Atlantic Technology Ventures, Inc. (not TG Therapeutics, Inc.) for the reporting period ending January 31, 2001. The filing discloses a material event involving the sale of assets by Optex Ophthalmologics, Inc., a majority-owned subsidiary of Atlantic.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The only specific financial value disclosed is a $3,000,000 cash proceeds threshold referenced in a prior agreement with investors.
Material Changes
- Asset Sale: On January 31, 2001, Atlantic and Optex signed an asset purchase agreement to sell substantially all of Optex's assets to Bausch & Lomb Incorporated and its subsidiary.
- Investor Agreement Status: The timely signing of the agreement on January 31, 2001, prevented a "Repurchase Event" under the Purchase Agreement with BH Capital Investments, L.P. and Excalibur Limited Partnership. This event would have been triggered if Optex failed to sign a binding agreement for $3,000,000 in cash proceeds by that date.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the asset sale. The primary contingency addressed was the avoidance of a mandatory stock repurchase obligation to investors, which was successfully averted by meeting the January 31 deadline.
Investor Verification Checklist
- Verify the final closing date and actual cash proceeds received from the Bausch & Lomb asset purchase, as the filing only confirms the signing of the agreement.
- Review the terms of the Purchase Agreement with BH Capital Investments and Excalibur Limited Partnership to understand the remaining obligations now that the "Repurchase Event" was avoided.
- Confirm the impact of the Optex asset sale on Atlantic's consolidated financial statements in subsequent filings (e.g., Form 10-Q or 10-K).